Human Recombinant ALPL protein, His Tag (V2LY-0526-LY2034)

Name: Human Recombinant ALPL protein, His Tag
SKU: V2LY-0526-LY2034
Rating: 5 (1 reviews)

See all ALPL antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant ALPL protein, His Tag consist of Amino Acid: 1-502 and predicts a molecular mass of 55 kDa.

Molecule Mass

55 kDa

Sequence

Amino Acid: 1-502

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

≥95% as determined by SDS-PAGE.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile Sodium phosphate, NaCl, Imidazole, DTT, Glycerol

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

Alkaline Phosphatase, Liver/Bone/Kidney

Function

This isozyme plays a key role in skeletal mineralization by regulating levels of diphosphate (PPi).

Biological Process

Cellular response to organic cyclic compound Source: Ensembl
Cementum mineralization Source: Ensembl
Dephosphorylation Source: GO_Central
Developmental process involved in reproduction Source: Ensembl
Endochondral ossification Source: Ensembl
Osteoblast differentiation Source: UniProtKB
Response to antibiotic Source: Ensembl
Response to glucocorticoid Source: Ensembl
Response to lipopolysaccharide Source: Ensembl
Response to vitamin D Source: BHF-UCL
Skeletal system development Source: ProtInc

Cellular Location

Cell membrane

Involvement in disease

Hypophosphatasia (HOPS): A metabolic bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase. Four forms are distinguished, depending on the age of onset: perinatal, infantile, childhood and adult type. The perinatal form is the most severe and is almost always fatal. The adult form is mild and characterized by recurrent fractures, osteomalacia, rickets, and loss of teeth. Some cases are asymptomatic, while some patients manifest dental features without skeletal manifestations (odontohypophosphatasia).
Hypophosphatasia childhood type (HOPSC): A bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase.
Hypophosphatasia infantile type (HOPSI): A severe bone disease characterized by defective skeletal mineralization and biochemically by deficient activity of the tissue non-specific isoenzyme of alkaline phosphatase. Three more or less distinct types of infantile hypophosphatasia can be identified: (1) type 1 with onset in utero or in early postnatal life, craniostenosis, severe skeletal abnormalities, hypercalcemia, and death in the first year or so of life; (2) type 2 with later, more gradual development of symptoms, moderately severe 'rachitic' skeletal changes and premature loss of teeth; (3) type 3 with no symptoms, the condition being determined on routine studies.

PTM

N-glycosylated.

Vimalraj, S. (2020). Alkaline phosphatase: structure, expression and its function in bone mineralization. Gene, 754, 144855.

Pietraszek, A., Ledwójcik, G., Lewandowska-Łańcucka, J., Horak, W., Lach, R., Łatkiewicz, A., & Karewicz, A. (2020). Bioactive hydrogel scaffolds reinforced with alkaline-phosphatase containing halloysite nanotubes for bone repair applications. International Journal of Biological Macromolecules, 163, 1187-1195.

Haarhaus, M., Gilham, D., Kulikowski, E., Magnusson, P., & Kalantar-Zadeh, K. (2020). Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease. Current opinion in nephrology and hypertension, 29(1), 4.

Li, N., Zhou, L., Xie, W., Zeng, D., Cai, D., Wang, H., ... & Li, L. (2019). Alkaline phosphatase enzyme-induced biomineralization of chitosan scaffolds with enhanced osteogenesis for bone tissue engineering. Chemical Engineering Journal, 371, 618-630.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant ALPL protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Cynomolgus Recombinant ALPL protein, Biotin Conjugated, His & AVI Tag (CAT#: V2LY-0526-LY1370)

Human Recombinant ALPL protein, Biotin Conjugated, AVI Tag (CAT#: V2LY-0526-LY2033)

Human Recombinant ALPL protein, His Tag-1 (CAT#: V2LY-0526-LY2035)

Human Recombinant ALPL protein, hFc Tag (CAT#: V2LY-0526-LY2036)

Human Recombinant ALPL protein, His Tag-2 (CAT#: V2LY-0526-LY2037)

Mouse Recombinant ALPL protein, hFc Tag (CAT#: V2LY-0526-LY7793)

Mouse Recombinant ALPL protein, His Tag (CAT#: V2LY-0526-LY7794)

Related Products

Mouse Anti-ALPL Recombinant Antibody (D1) (CAT#: CBMAB-A2423-YC)

Rabbit Anti-ALPL Recombinant Antibody (EG156) (CAT#: CBMAB-EN169-LY)

Mouse Anti-ALPL Antibody (B4-78) (CAT#: CBMAB-1009CQ)

Human Recombinant ALPL protein, hFc Tag (CAT#: V2LY-0526-LY2036)

Mouse Anti-ALPL Recombinant Antibody (C4) (CAT#: CBMAB-A2427-YC)

Mouse Anti-ALPL Recombinant Antibody (3A7) (CAT#: CBMAB-A0315-LY)

Mouse Anti-ALPL Recombinant Antibody (VIAP1) (CAT#: CBMAB-A2422-YC)

Mouse Anti-ALPL Recombinant Antibody (CBT3985) (CAT#: V2LY-0625-LY2692)

Rabbit Anti-ALPL Recombinant Antibody (CAP121) (CAT#: CBMAB-AP294LY)

Mouse Anti-ALPL Recombinant Antibody (W8B2B10) (CAT#: CBMAB-A2426-YC)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry